Skip to main content
. Author manuscript; available in PMC: 2016 May 13.
Published in final edited form as: Cancer Discov. 2012 Feb 28;2(3):260–269. doi: 10.1158/2159-8290.CD-11-0242

Figure 2. nab-paclitaxel targets the tumor epithelial cells.

Figure 2

A) 8 KPC cell lines were exposed to a dose range of paclitaxel, nab-paclitaxel, docetaxel, or gemcitabine for 3 days to determine the GI50 of each agent. Data is representative of four independent experiments. B) 3 KPC cell lines were exposed to sub-GI50 levels of agents. Cells were pre-treated with DMSO or 10μM paclitaxel for 24 hours and/or treated with 30nM gemcitabine for 2 days. Data is representative of two independent experiments. The dotted lines represent predicted additive effect of combination therapy. Proliferation (C) and apoptosis (D) in tumors was measured via quantitative immunohistochemistry for Ki67 and cleaved caspase 3, respectively. (n=8) E) 10-20 high powered fields per tumor were quantified by performing co-immunofluorescence for cleaved caspase 3 and E-cadherin. (n≥9)